Drug Search Results
More Filters [+]


Alternative Names: dicloxacillin, dycill, pathocil, dynapen
Latest Update: 2024-01-04
Latest Update Note: News Article

Product Description

Dicloxacillin is an oral, second generation penicillin antibiotic that is used to treat bacterial infections caused by penicillinase-resistant staphylococci. Dicloxacillin has been linked to rare instances of clinically apparent, idiosyncratic liver injury. Dicloxacillin is a broad-spectrum, semi-synthetic, beta-lactam, penicillin antibiotic with bactericidal and beta-lactamase resistant activity. Dicloxacillin binds to penicillin binding proteins (PBP) located on the inner membrane of the bacterial cell wall. It also inhibits the cross-linkage of peptidoglycan, a critical component of bacterial cell walls. This leads to the inhibition of bacterial cell wall synthesis and eventually causes cell lysis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dicloxacillin)

Mechanisms of Action: PBP Antagonist,Cell Wall Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Bangladesh | Brazil | Colombia | Denmark | Dominican Republic | Ecuador | Egypt | Germany | Hong Kong | Iceland | India | Italy | Mexico | New Zealand | Norway | Pakistan | Peru | Portugal | Sweden | Taiwan | Thailand | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Thomas Benfield
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dicloxacillin

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Community-Acquired Infections|Soft Tissue Infections



Trial Status


Primary Completion Date

Probability of Success




Community-Acquired Infections|Soft Tissue Infections


Recent News Events